2. Search Result
Search Result
Results for "

diabetic ZDF/Crl-Lepra rats

" in MedChemExpress (MCE) Product Catalog:

2865

Inhibitors & Agonists

1

Screening Libraries

14

Fluorescent Dyes

52

Biochemical Assay Reagents

223

Peptides

2

MCE Kits

41

Inhibitory Antibodies

582

Natural
Products

113

Isotope-Labeled Compounds

9

Click Chemistry

25

Oligonucleotides

4

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-66009
    Epalrestat
    5+ Cited Publications

    ONO2235

    		 Aldose Reductase Metabolic Disease Inflammation/Immunology Cancer
    Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy .
    Epalrestat
  • HY-B1670A
    (-)-Isoproterenol hydrochloride
    1 Publications Verification

    Levisoprenaline hydrochloride; Proternol L hydrochloride

    		 Caspase TNF Receptor Metabolic Disease
    (-)-Isoproterenol (Levisoprenalinel) hydrochloride is the R-isomer of Isoproterenol. (-)-Isoproterenol hydrochloride can reduce the cleavage of caspase 3 and TNFα levels in retinal endothelial cells (REC). (-)-Isoproterenol hydrochloride can be used for the study of diabetic retinopathy .
    (-)-Isoproterenol hydrochloride
  • HY-121401A
    (−)-Myrtenal

    (1R)-(−)-Myrtenal; (−)-(1R,5S)-Myrtenal

    		 Akt Metabolic Disease Cancer
    (-)-Myrtenal ((1R)-(-)-Myrtenal) is an orally active terpene with antitumour activity. (-)-Myrtenal ameliorates hyperglycemia by enhancing GLUT2 through Akt in the skeletal muscle and liver of diabetic rats .
    (−)-Myrtenal
  • HY-142240
    Crisugabalin

    HSK16149

    		 Calcium Channel Neurological Disease
    Crisugabalin is an orally active, selective ligand for the α2δ subunit of voltage-gated calcium channels, with a target IC50 of 3.96 nM in rats. Crisugabalin inhibits the binding of [ 3H]gabapentin to the α2δ subunit, reduces calcium influx, decreases neuronal excitability, and impairs nociceptive transmission. Crisugabalin alleviates mechanical allodynia, neuropathic pain and inflammatory pain in rats, and reduces phase II pain behaviors. Crisugabalin can be used in research related to chronic pain, neuropathic pain, diabetic neuropathy, fibromyalgia, inflammatory pain, diabetic peripheral neuropathy and postherpetic neuralgia.
    Crisugabalin
  • HY-B0093A
    Benazepril hydrochloride
    2 Publications Verification

    CGS14824A

    		 Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS) Akt Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Benazepril (CGS14824A) hydrochloride is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril hydrochloride inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. In addition, Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria. Benazepril hydrochloride can be used in the study of hypertension, heart failure and diabetic nephropathy .
    Benazepril hydrochloride
  • HY-B1392
    Esmolol hydrochloride
    3 Publications Verification

    		 Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor Cardiovascular Disease Endocrinology Cancer
    Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol hydrochloride attenuates post resuscitation myocardial dysfunction. Esmolol hydrochloride improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .
    Esmolol hydrochloride
  • HY-14447
    Bilastine

    		Histamine Receptor Inflammation/Immunology Endocrinology
    Bilastine is an oral histamine H1-receptor antagonist. Bilastine can be used for allergic rhinitis and urticaria studies, and it also improves diabetic nephropathy in mice, showing safety for the central nervous system .
    Bilastine
  • HY-17374
    Benfotiamine
    1 Publications Verification

    S-Benzoylthiamine O-monophosphate

    		 SARS-CoV HIV Infection Metabolic Disease Inflammation/Immunology
    Benfotiamine (S-Benzoylthiamine O-monophosphate) is a vitamin B1 derivative that exhihibits potent antioxidative and anti-inflammatory activity. Benfotiamine can be used for the research of various secondary diabetic complications. Benfotiamine also can be used in infectious diseases such as HIV and COVID-19 .
    Benfotiamine
  • HY-19687
    Zopolrestat
    1 Publications Verification

    CP73850

    		 Aldose Reductase Metabolic Disease
    Zopolrestat (CP73850) is a potent, orally active aldose reductase (AR) inhibitor with an IC50 of 3.1 nM. Zopolrestat is used for the research of diabetic complications .
    Zopolrestat
  • HY-103290
    R715

    		Bradykinin Receptor Others
    R715 is a selective bradykinin B1 receptor antagonist. R715 significantly attenuates the hyperalgesic effect developed in Streptozotocin(HY-13753)-diabetic mice .
    R715
  • HY-N2555
    Tilianin
    2 Publications Verification

    		 Others Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Tilianin is an active flavonoid glycoside found in many medical plants, with potential anti-hypertensive, myocardial-protective, anti-diabetic, anti-hyperlipidemic, anti-inflammatory and antioxidant effects .
    Tilianin
  • HY-P11069
    Kidney-targeting peptide

    		Biochemical Assay Reagents Metabolic Disease
    Kidney-targeting peptide is a kidney-targeting peptide (KTP). Kidney-targeting peptide significantly enhances the renal targeting ability of Isoquercitrin (HY-N1445). Kidney-targeting peptide can be used in diabetic nephropathy research .
    Kidney-targeting peptide
  • HY-112482
    ABT-702
    3 Publications Verification

    		 Adenosine Kinase Adenosine Receptor Neurological Disease Inflammation/Immunology
    ABT-702 (Adenosine Kinase Inhibitor) is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research .
    ABT-702
  • HY-164781
    KOTX1
    1 Publications Verification

    MBE1

    		 Aldehyde Dehydrogenase (ALDH) Metabolic Disease
    KOTX1 is an orally active and selective ALDH1A3 inhibitor. KOTX1 improves glucose tolerance, insulin secretion and blood sugar levels in diabetic mouse models .
    KOTX1
  • HY-B0093
    Benazepril
    2 Publications Verification

    CGS14824A free base

    		 Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS) Cardiovascular Disease Cancer
    Benazepril (CGS14824A free base) is an orally active angiotensin-converting enzyme (ACE) inhibitor to reduce angiotensin-II production. Benazepril inhibits oxidative stress and inhibits apoptosis by the PI3K/Akt signaling pathway. Benazepril improves diabetic nephropathy and decreases proteinuria. Benazepril can be used in the study of hypertension, heart failure and diabetic nephropathy .
    Benazepril
  • HY-15314
    Ranirestat
    1 Publications Verification

    AS-3201

    		 Aldose Reductase Neurological Disease Metabolic Disease
    Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas .
    Ranirestat
  • HY-117623
    PF-06685249

    PF-249

    		 AMPK Metabolic Disease
    PF-06685249 (PF-249) is a potent and orally active allosteric AMPK activator with an EC50 of 12 nM for recombinant AMPK α1β1γ1. PF-06685249 improves renal function in ZSF-1 rats with diabetic nephropathy. PF-06685249 can be used for diabetic nephropathy research .
    PF-06685249
  • HY-W020086
    2,3-Diaminophenazine

    2,3-Phenazinediamine; NNC39-0028

    		 DNA Alkylator/Crosslinker Fluorescent Dye Metabolic Disease
    2,3-Diaminophenazine (2,3-Phenazinediamine) is an orally active amino derivative of phenazine. 2,3-Diaminophenazine can intercalate into DNA. 2,3-Diaminophenazine triggers photochemical reactions. 2,3-Diaminophenazine inhibits vascular hypertrophy and tissue AGE deposition in diabetic rats. 2,3-Diaminophenazine can be used for luminescence and diabetes research .
    2,3-Diaminophenazine
  • HY-N2531
    Notoginsenoside Fc

    		Autophagy Cardiovascular Disease
    Notoginsenoside Fc, a protopanaxadiol- (PPD-) type saponin isolated from the leaves of Panax notoginseng, effectively counteracts platelet aggregation. Notoginsenoside Fc can accelerate reendothelialization following vascular injury in diabetic rats by promoting autophagy .
    Notoginsenoside Fc
  • HY-10655
    Palosuran
    4 Publications Verification

    ACT-058362

    		 Urotensin Receptor Cardiovascular Disease
    Palosuran (ACT-058362) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran can improves pancreatic and renal function in diabetic rats .
    Palosuran
  • HY-107384A
    Asimadoline hydrochloride

    EMD-61753 hydrochloride

    		 Opioid Receptor Neurological Disease Metabolic Disease Inflammation/Immunology
    Asimadoline (EMD-61753) hydrochloride is an orally active, selective and peripherally active κ-opioid agonist with IC50s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline hydrochloride has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline hydrochloride ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .
    Asimadoline hydrochloride
  • HY-18967
    Caficrestat

    AT-001; Aldose reductase-IN-1

    		 Aldose Reductase Metabolic Disease
    Caficrestat (AT-001) is an orally active aldose reductase inhibitor. Caficrestat can be used in the study of diabetic cardiomyopathy .
    Caficrestat
  • HY-14791
    Ibipinabant
    1 Publications Verification

    SLV319; BMS-646256

    		 Cannabinoid Receptor Metabolic Disease
    Ibipinabant (SLV319) is a potent, selective and orally active antagonist of cannabinoid CB1 receptor, with a Ki of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (Ki=7943 nM). Ibipinabant can be used for the research of obesity and diabetic .
    Ibipinabant
  • HY-W166297
    Esculin sesquihydrate
    5 Publications Verification

    		 p38 MAPK Cancer
    Esculin sesquihydrate, a fluorescent coumarin glucoside, is an active ingredient of ash bark. Esculin sesquihydrate ameliorates cognitive impairment in experimental diabetic nephropathy (DN), and exerts anti?oxidative stress and anti?inflammatory effects, via the MAPK signaling pathway .
    Esculin sesquihydrate
  • HY-W011240
    Hydroflumethiazide

    Methforylthiazidine; Rontyl

    		 Sodium Channel Chloride Channel Metabolic Disease Endocrinology
    Hydroflumethiazide (Methforylthiazidine) is an orally active and potent thiazide diuretic. Hydroflumethiazide possesses the ability to directly stimulate A cell secretion in the normal and alloxan diabetic pancreas .
    Hydroflumethiazide
  • HY-106103
    Seglitide

    MK-678; L-363586

    		 Somatostatin Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Seglitide (MK-678) is an orally active, selective SSTR2 agonist and somatostatin analog. Seglitide also acts as a competitive Somatostatin receptor antagonist, with pA2 values of 6.50, 6.24 and 6.09 against SS14, SS25 and SS28, respectively. Seglitide produces only weak, transient inhibition of myocardial contractility in isolated right atria of guinea pigs. Seglitide inhibits glucagon secretion and reduces circulating insulin levels. Seglitide causes a sustained, reversible reduction in elevated systolic blood pressure in streptozotocin (HY-13753)-induced diabetic rats, but exerts no effect on spontaneously hypertensive rats. Seglitide induces membrane hyperpolarization and inhibits electrical excitability. Seglitide induces concentration-dependent contraction and significant desensitization in isolated distal colon of rats. Seglitide can be used in research related to hypertension complicated with insulin-dependent diabetes mellitus .
    Seglitide
  • HY-116239
    Zenarestat
    1 Publications Verification

    		 Aldose Reductase Neurological Disease Metabolic Disease
    Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats .
    Zenarestat
  • HY-106246
    Pruvanserin

    EMD 281014 free base; LY 2422347

    		 5-HT Receptor Neurological Disease Metabolic Disease
    Pruvanserin (EMD 281014 free base) is a selective 5-HT2A receptor antagonist. Pruvanserin alleviates tactile allodynia in diabetic rats. Pruvanserin can also be used for research of insomnia .
    Pruvanserin
  • HY-P1131
    M617

    		Neuropeptide Y Receptor Cardiovascular Disease
    M617 is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats .
    M617
  • HY-162325
    WJ-39

    		Aldose Reductase Mitochondrial Metabolism Apoptosis Mitophagy Metabolic Disease
    WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis .
    WJ-39
  • HY-66009R
    Epalrestat (Standard)

    ONO2235 (Standard)

    		 Reference Standards Aldose Reductase Metabolic Disease Inflammation/Immunology Cancer
    Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy .
    Epalrestat (Standard)
  • HY-164368
    GLUT4 activator 2

    		Phosphodiesterase (PDE) Insulin Receptor Metabolic Disease
    GLUT4 activator 2 (C59) is an insulin sensitizer, which can be used for research of diabetic diseases. GLUT4 activator 2 improves glucose uptake and insulin sensitivity in rodents. GLUT4 activator 2 interacts with Unc119 and Unc119B resulting in increased insulin sensitivity and GLUT4 translocation .
    GLUT4 activator 2
  • HY-117702
    RB 101

    		Prolyl Endopeptidase (PREP) Aminopeptidase Opioid Receptor Dopamine Receptor Drug Intermediate Neurological Disease Metabolic Disease Inflammation/Immunology
    RB 101 is a blood-brain barrier-crossing prodrug as well as aminopeptidase N and neutral endopeptidase-24.11 inhibitor. RB 101 blocks enkephalin breakdown, elevates extracellular enkephalin levels and activate δ-opioid receptor and dopamine D1 receptor. RB 101 can be used for the research of pain, depressive syndromes, and diabetic neuropathy .
    RB 101
  • HY-131929
    AE-ITU dihydrobromide

    		NO Synthase Inflammation/Immunology
    AE-ITU dihydrobromide is the dihydrobromide form of AE-ITU. AE-ITU dihydrobromide is a selective inhibitor for inducible NO synthase (iNOS), and attenuates the liver dysfunction caused by endotoxaemia in rats .
    AE-ITU dihydrobromide
  • HY-106915
    SG-210

    SPR 210

    		 Aldose Reductase Neurological Disease Metabolic Disease
    SG-210 (SPR 210) is an orally active and selective aldose reductase (AR) inhibitor. SG-210 has IC50 values of 9.5 nM and 10 nM for AR from porcine lens and human placenta, respectively. SG-210 can inhibit sorbitol accumulation and ameliorate diabetic neuropathy and retinopathy in Streptozotocin (HY-13753)-induced diabetic rats. SG-210 can be used in the research of diseases such as diabetes-related complications .
    SG-210
  • HY-144289
    BMS-820132

    		Glucokinase Metabolic Disease
    BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC50 of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .
    BMS-820132
  • HY-107384
    Asimadoline

    EMD-61753

    		 Opioid Receptor Neurological Disease Metabolic Disease Inflammation/Immunology
    Asimadoline (EMD-61753) is an orally active, selective and peripherally active κ-opioid agonist with IC50s of 5.6 nM (guinea pig) and 1.2 nM (human recombinant). Asimadoline has low permeability across the blood brain barrier and has peripheral anti-inflammatory actions. Asimadoline ameliorates allodynia in diabetic rats and has the potential for irritable bowel syndrome (IBS) .
    Asimadoline
  • HY-N9363
    Corymbiferin

    		Others Metabolic Disease
    Corymbiferin is one of active constituents, responsible for anti-diabetic properties. Corymbiferin improves antioxidant capacity and carbohydrate metabolism in diabetic rats, along with the improvement of histopathology of livers and pancreatic β cells .
    Corymbiferin
  • HY-145604
    Vicasinabin

    RG7774

    		 Cannabinoid Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Vicasinabin (RG7774) is an orally active, selective, and full CB2R agonist, with EC50 values of 2.81 nM and 2.60 nM for human CB2R and mouse CB2R, respectively. Vicasinabin inhibits inflammation, reduces leukocyte adhesion and decreases vascular permeability by selectively activating CB2R. Vicasinabin can be used in the researches for diabetic retinopathy, uveitis and laser-induced choroidal neovascularization .
    Vicasinabin
  • HY-W662576
    KVD-001

    		Kallikrein Cardiovascular Disease Metabolic Disease Endocrinology
    KVD-001 is a potent plasma kallikrein inhibitor. KVD-001 can be used for diabetic macular edema research .
    KVD-001
  • HY-134191
    Cryptochrome modulator 1

    		Cryptochrome Metabolic Disease
    Cryptochrome modulator 1 (Compound 50) is a cryptochrome modulator. Cryptochrome modulator 1 reduces glucose intolerance in diabetic mice .
    Cryptochrome modulator 1
  • HY-P1556
    Vasonatrin Peptide (VNP)

    		PKG Cardiovascular Disease
    Vasonatrin Peptide (VNP) is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). Vasonatrin peptide possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP. Vasonatrin Peptide protects the diabetic heart against ischemia-reperfusion injury by inhibiting ER stress via the cGMP-PKG signaling pathway .
    Vasonatrin Peptide (VNP)
  • HY-B1670
    (-)-Isoproterenol

    Levisoprenalinel; Proternol L

    		 Caspase TNF Receptor Metabolic Disease
    (-)-Isoproterenol (Levisoprenalinel) is the R-isomer of Isoproterenol. (-)-Isoproterenol can reduce the cleavage of caspase 3 and TNFα levels in retinal endothelial cells (REC). (-)-Isoproterenol can be used for the study of diabetic retinopathy .
    (-)-Isoproterenol
  • HY-14923
    Ilepatril

    AVE 7688

    		 Angiotensin-converting Enzyme (ACE) Metabolic Disease
    Ilepatril, a dual inhibitor of angiotensin-converting enzyme (ACE) and neutral endopeptidase, has inhibitory effects in the type 2 diabetic nephropathy model in obese Zucker diabetic fatty (ZDF) rats. Ilepatril significantly reduced albuminuria in a dose-dependent manner and may be a strategy distinct from metabolic control to inhibit type 2 diabetic nephropathy .
    Ilepatril
  • HY-174145
    GLUT4 activator 3

    		GLUT Metabolic Disease
    GLUT4 activator 3 (Compound 13a) is an antidiabetic agent targeting GLUT4 translocation in skeletal muscle. GLUT4 activator 3 can promote the translocation of glucose transporter 4 (GLUT4) in skeletal muscle cells. GLUT4 activator 3 reduces blood glucose in STZ-induced diabetic rats .
    GLUT4 activator 3
  • HY-W010655
    Fasiglifam hemihydrate

    TAK-875 hemihydrate

    		 Free Fatty Acid Receptor Metabolic Disease
    Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC50 of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury .
    Fasiglifam hemihydrate
  • HY-139467
    PF-04577806

    		SHP2 PKC Metabolic Disease
    PF-04577806 is a potent, selective and ATP competitive PKC inhibitor. PF-04577806 shows potent inhibitory activity towards PKCα, PKCβI, PKCβII, PKCγ, and PKCθ with IC50s of 2.4 nM, 8.1 nM, 6.9 nM, 45.9 nM, and 29.5 nM, respectively. PF-04577806 can reverse retinal vascular leakage in diabetic rats .
    PF-04577806
  • HY-143476
    Plasma kallikrein-IN-2

    		Kallikrein Cardiovascular Disease Metabolic Disease
    Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
    Plasma kallikrein-IN-2
  • HY-112488
    EXEL-0346

    		Glucosylceramide Synthase (GCS) Metabolic Disease
    EXEL-0346 is an orally active glucosylceramide synthase (GCS) inhibitor, with an IC50 of 2 nM. EXEL-0346 combined with insulin increases pAkt. EXEL-0346 effectively reduces the levels of Glucosylceramide, Lactosylceramide and GM3. EXEL-0346 improves obesity and diabetes .
    EXEL-0346
  • HY-160602
    CPL207280

    		Free Fatty Acid Receptor Metabolic Disease
    CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .
    CPL207280

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: